{"id":"apatinib-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Proteinuria"}]},"_chembl":{"chemblId":"CHEMBL3186534","moleculeType":"Small molecule","molecularWeight":"397.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apatinib is a tyrosine kinase inhibitor that selectively targets VEGFR2, preventing new blood vessel formation that tumors depend on for growth and metastasis. Capecitabine is a prodrug that converts to 5-fluorouracil in tumor tissue, interfering with nucleotide synthesis and DNA replication. The combination leverages anti-angiogenic and cytotoxic mechanisms to enhance anti-tumor efficacy.","oneSentence":"Apatinib inhibits vascular endothelial growth factor receptor 2 (VEGFR2) to block tumor angiogenesis, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:01.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer or gastroesophageal junction cancer (in combination)"},{"name":"Other solid tumors under investigation in phase 3 trials"}]},"trialDetails":[{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT06281886","phase":"PHASE2","title":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity","enrollment":170},{"nctId":"NCT03813784","phase":"PHASE3","title":"A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-07","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":885},{"nctId":"NCT05934331","phase":"PHASE2","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","status":"RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2023-07-27","conditions":"Malignant Neoplasms of Digestive Organs","enrollment":276},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":"Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","enrollment":140},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":"Metastatic Pancreatic Carcinoma","enrollment":43},{"nctId":"NCT03228043","phase":"NA","title":"Apatinib for Resectable Colorectal Cancer","status":"WITHDRAWN","sponsor":"Nanchong Central Hospital","startDate":"2020-03-01","conditions":"Apatinib, Outcome, Fatal, Colorectal Cancer","enrollment":""},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06464614","phase":"PHASE2","title":"Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2024-07-15","conditions":"Esophageal Cancer","enrollment":54},{"nctId":"NCT06339281","phase":"PHASE2","title":"A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Huiping","startDate":"2024-05-01","conditions":"Advanced Breast Cancer","enrollment":68},{"nctId":"NCT06238752","phase":"PHASE2","title":"First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2021-03-01","conditions":"Advanced Gastric Adenocarcinoma","enrollment":33},{"nctId":"NCT04720131","phase":"PHASE2","title":"Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-01","conditions":"Biliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy","enrollment":28},{"nctId":"NCT03472365","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-02","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":67},{"nctId":"NCT04803539","phase":"PHASE2, PHASE3","title":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-01","conditions":"Breast Cancer","enrollment":260},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT04338438","phase":"PHASE2","title":"Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2015-05-01","conditions":"Gastric Cancer","enrollment":37},{"nctId":"NCT04296370","phase":"PHASE3","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-13","conditions":"Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","enrollment":474},{"nctId":"NCT04411706","phase":"PHASE2","title":"A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Xin-Hua Xu","startDate":"2020-06-21","conditions":"Hepatocellular Carcinoma","enrollment":46},{"nctId":"NCT04202978","phase":"PHASE1, PHASE2","title":"Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer","status":"UNKNOWN","sponsor":"Zhongshan Hospital Xiamen University","startDate":"2020-03-01","conditions":"Hepatic Metastasis of Colorectal Cancer","enrollment":23},{"nctId":"NCT03986385","phase":"PHASE3","title":"Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2019-06-01","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":180},{"nctId":"NCT03349866","phase":"PHASE2","title":"A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2017-11-30","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":48},{"nctId":"NCT03229096","phase":"PHASE2","title":"Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-02-01","conditions":"Chemotherapy Effect, Chemotherapeutic Toxicity, Gastric Cancer","enrollment":35},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03889626","phase":"PHASE3","title":"The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-03-22","conditions":"Stomach Neoplasms, Gastrointestinal Neoplasms, Stomach Diseases","enrollment":242},{"nctId":"NCT03775928","phase":"PHASE2","title":"Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2018-12-18","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT03609489","phase":"PHASE2","title":"A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2018-09-10","conditions":"Biliary Carcinoma","enrollment":40},{"nctId":"NCT03598348","phase":"PHASE3","title":"Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2018-01-16","conditions":"Gastric Cancer","enrollment":288},{"nctId":"NCT03599778","phase":"PHASE1, PHASE2","title":"XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2018-09-01","conditions":"Gastric Carcinoma","enrollment":52},{"nctId":"NCT03531931","phase":"","title":"Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2018-05","conditions":"Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety","enrollment":20},{"nctId":"NCT03412994","phase":"PHASE2","title":"Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Liqiang Zhong","startDate":"2018-02-28","conditions":"Colorectal Neoplasms","enrollment":60},{"nctId":"NCT03086785","phase":"PHASE2","title":"Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2016-11-24","conditions":"Breast Cancer Metastatic","enrollment":120},{"nctId":"NCT03355612","phase":"PHASE3","title":"XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12-20","conditions":"Gastric Carcinoma","enrollment":456},{"nctId":"NCT03210064","phase":"PHASE2","title":"Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Hui ting Xu，MD","startDate":"2017-05-04","conditions":"Metastatic Colorectal Cancer","enrollment":42},{"nctId":"NCT03114085","phase":"PHASE2","title":"Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-05-20","conditions":"Hepatocellular Carcinoma","enrollment":170},{"nctId":"NCT03132025","phase":"PHASE2","title":"Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2017-04-30","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT02829385","phase":"PHASE2","title":"Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Shoucheng Ma","startDate":"2016-06","conditions":"Colorectal Neoplasms","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["apatinib","capecitabine"],"phase":"phase_3","status":"active","brandName":"Apatinib+Capecitabine","genericName":"Apatinib+Capecitabine","companyName":"Huazhong University of Science and Technology","companyId":"huazhong-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apatinib inhibits vascular endothelial growth factor receptor 2 (VEGFR2) to block tumor angiogenesis, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells. Used for Gastric cancer or gastroesophageal junction cancer (in combination), Other solid tumors under investigation in phase 3 trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}